USD 9.5 billion
Report ID:
SQMIG35A2516 |
Region:
Global |
Published Date: February, 2025
Pages:
219
|Tables:
63
|Figures:
75
Diabetic Retinopathy Market size was valued at USD 9.5 billion in 2023 and is poised to grow from USD 10.16 billion in 2024 to USD 17.32 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).
The rising incidence of diabetes, the increasing number of seniors, and a growing number of diabetes-related blindness are among the primary drivers expected to drive market expansion throughout the forecast period. The market is also being spurred forward by rising diabetes awareness and new product introductions. Diabetes is a major and developing global condition in which the pancreas' inability to make insulin leads to a rise in blood sugar levels. Damage to blood capillaries in the retina causes diabetic retinopathy.
High levels of sugar in the blood & poor monitoring of these constantly shifting BG levels are thought to be risk factors for diabetic retinal degeneration. Early detection of Type 2 diabetes in patients, medication correction, continuous self-monitoring by patients utilizing modern instruments, and adoption of a healthy lifestyle may prevent retinal blood vessel damage, lowering the incidence of diabetic retinopathy amongst patients. In spite of the diabetic population's efforts, diabetic retinopathy might result in irreversible blindness, depending on its current stage and severity.
Market participants have focused on the early detection of diabetic retinopathy. Check Eye, a Ukraine-based healthtech business creating a powered by AI cloud-based platform to determine retinopathy due to diabetes, for example, introduced a mobile solution to organize screening for DR for people with diabetes and their families in January 2023. The screening was assisted and supported by the Ukrainian Diabetic Federation & the Filatov Centre for Eye Diseases.
Furthermore, according to the Royal National Institution of Blind People (RNIB), diabetic retinal degeneration was one of the top causes of blindness in the United Kingdom. Rising consumer awareness levels and rising healthcare expenditure are two more aspects that are expected to drive market expansion. Furthermore, according to the WHO, the world's aging population is expected to triple by 2050, compared to 2020, making it critical to keep up a healthy lifestyle, reduce obesity, and regularly check BG levels in vulnerable groups.
Market snapshot - 2025-2032
Global Market Size
USD 9.5 billion
Largest Segment
Proliferative
Fastest Growth
Proliferative
Growth Rate
6.9% CAGR
To get more reports on the above market click here to Buy The Report
Global Diabetic Retinopathy Market is segmented by Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. Based on Treatment, the market is segmented into Medication, Through Device, Surgery and Others. Based on Diagnosis, the market is segmented into Fluorescein Angiography, Optical Coherence Tomography and Others. Based on Route of Administration, the market is segmented into Oral, Intravitreal Injections, Intravitreal Implants, Topical Eye Drops, Laser Surgery, Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Analysis by Management
Anti-VEGF medications accounted for the greatest percentage of revenue of 92.8% in 2023 because to their effectiveness and efficacy in the management of diabetic retinopathy. Anti-VEGF medications are commonly used to treat Proliferative Diabetes Retinopathy (PDR). Anti-VEGF drugs have been shown to be more effective in PDR, particularly in situations of vitreous hemorrhage, neovascular a condition called and prior to vitrectomy.
In contrast to anti-VEGF drugs, intraocular steroids injection is a new method of treating diabetic retinopathy (DR) & diabetic macular edema (DME) that is progressively gaining traction. Corticosteroid-based medicines are used in the injections to inhibit cellular growth. Triamcinolone (Durezol) has the best therapeutic efficacy and a large market presence among all corticosteroids studied. As retinopathy care tools, other components include surgery with lasers and vitrectomy.
Analysis by Type
Non-proliferative diabetic retinopathy dominated the diabetes-related retinopathy market in 2023, accounting for 70.5% of total revenue. The growing senior population and increased occurrences of diabetes-related blindness are the main reasons for its high share. Additionally, rising demand for routine retinal screening for long-term diabetes patients is likely to drive category growth. The proliferating diabetic retinopathy segment, on the other hand, is predicted to grow at a 6.8% CAGR from 2023 to 2030.
The Proliferative Diabetic Retinopathy (PDR) sector is predicted to grow at a faster rate of 5.6% during the forecast period. It is a severe stage of retinopathy in which weak blood vessels form within the layers of the retina and vitreous humor, resulting in vision impairment & blindness. It can cause macular edema, which has no signs in the beginning. Thorough eye exams, which include tonometry, vision tests, and others, are used to diagnose it. It is managed with laser surgery, which causes blood vessels to shrink.
To get detailed analysis on other segments, Request For Free Sample Report
North America dominated the market, accounting for 37.8% of total revenue in 2023. Some of the market's drivers include the presence of modern healthcare infrastructure, favorable government activities pertaining to medication research, and the presence of substantial patient & practitioner awareness levels. One of the primary factors contributing to this region's huge share is the high market penetration of new goods such as anti-VEGF medications such as Lucentis, Avastin, and Eylea. High healthcare expenditure, increased patient knowledge of diabetes, the availability of well-established medical facilities, and a favorable reimbursement environment are some of the primary causes.
The Asia Pacific market is expected to grow at a 7.1% CAGR from 2023 to 2030, owing to the presence of high unmet medical requirements, as well as rapidly rising patient awareness about effective diabetes diagnostic procedures and rising medical costs in the developing nations of India and China. Latin America and the Middle East are also expected to experience profitable growth during the predicted period.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Diabetic Retinopathy Market Drivers
Rising Prevalence of Diabetes
The increasing global prevalence of diabetes is a significant driver for the diabetic retinopathy market. Diabetic retinopathy is a common complication of diabetes and affects many diabetic patients. The growing diabetic population contributes to the demand for diagnostic and treatment options for diabetic retinopathy.
Investing more in the infrastructure of healthcare
Better facilities and equipment are made possible by more funding. Among those with the necessary tools to identify and manage diabetic retinopathy are ophthalmology departments. A larger market for diabetic retinopathy may result from increased screening and treatment of more patients with stronger infrastructure.
Diabetic Retinopathy Market Restraints
Lack of Awareness and Access to Eye Care
Despite the growing prevalence of diabetic retinopathy, there is a lack of awareness about the condition and the importance of regular eye examinations among diabetic patients. Limited access to eye care facilities, particularly in remote or underserved areas, hampers early detection and timely treatment.
Hurdles in the Developing World: Lack of Professionals and Infrastructure Hinder Diabetic Retinopathy Market Growth
Developing economies face a double challenge in addressing diabetic retinopathy. Firstly, a scarcity of skilled professionals like ophthalmologists exists. This limits the capacity to diagnose and treat the condition effectively. Secondly, weak healthcare infrastructure translates to a lack of specialized equipment and facilities needed for proper diabetic retinopathy care. These factors combine to restrict the growth of the diabetic retinopathy market in these regions.
Request Free Customization of this report to help us to meet your business objectives.
To increase their market position, major players are focused on collaborations, partnerships, acquisitions, and other strategic operations. Industry leaders face growing competition with novel medication launches and regulatory approval of innovative management treatments, making it challenging for them to remain competitive in an ever-changing industry. However, market leaders' large investments in R&D are predicted to enhance market growth.
Eyenuk, a worldwide artificial intelligence (AI) healthcare company as well as the market leader in practical applications for AI Eye Evaluation and AI Predictive Biomarkers, will be able to market its EyeArt AI retinal screening device throughout the European Union in January 2023 for new uses such as identifying AMD (age-related macular degeneration) and glaucomatous damage to the optic nerve (a sign of glaucoma).
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
Our analysis reveals that the Diabetic Retinopathy Market is poised for significant growth, driven by several key factors. Firstly, the escalating prevalence of diabetes worldwide, coupled with the increasing aging population, contributes to a higher incidence of diabetes-related complications, including diabetic retinopathy. As diabetes continues to be a prevalent global health concern, the incidence of diabetes-related blindness is expected to rise, fueling demand for diagnostics and treatments for diabetic retinopathy. Additionally, heightened awareness about diabetes and its associated complications among healthcare professionals and patients alike is driving early detection and intervention efforts, further propelling market growth.
Furthermore, the introduction of innovative products and advancements in diagnostic and treatment technologies is expanding the scope of diabetic retinopathy management. These developments offer improved outcomes and enhanced patient care, fostering market expansion. Diabetes, a chronic condition characterized by the pancreas' inability to produce insulin, results in elevated blood sugar levels. Diabetic retinopathy, a complication of diabetes, occurs due to damage to the blood capillaries in the retina, highlighting the critical need for effective diagnostic and therapeutic solutions in the diabetic retinopathy market.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 9.5 billion |
Market size value in 2032 | USD 17.32 billion |
Growth Rate | 6.9% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Diabetic Retinopathy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Diabetic Retinopathy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Diabetic Retinopathy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Diabetic Retinopathy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Diabetic Retinopathy Market size was valued at USD 8.83 Billion in 2023 and is poised to grow from USD 9.4 Billion in 2024 to USD 15.44 Billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).
To increase their market position, major players are focused on collaborations, partnerships, acquisitions, and other strategic operations. Industry leaders face growing competition with novel medication launches and regulatory approval of innovative management treatments, making it challenging for them to remain competitive in an ever-changing industry. However, market leaders' large investments in R&D are predicted to enhance market growth. 'Novartis AG', 'Roche Holding AG', 'Bayer AG', 'Regeneron Pharmaceuticals, Inc.', 'Allergan plc (AbbVie Inc.)', 'Carl Zeiss Meditec AG', 'Topcon Corporation', 'Nidek Co., Ltd.', 'Optos plc (Nikon Corporation)', 'Bausch Health Companies Inc.', 'Alcon Inc.', 'Santen Pharmaceutical Co., Ltd.', 'Lumenis Ltd. (XIO Group)', 'Iridex Corporation', 'Leica Microsystems (Danaher Corporation)', 'StemCells Inc. (Microbot Medical Inc.)', 'Bioptigen, Inc. (Metabolic Technologies Inc.)', 'CenterVue SpA', 'Visunex Medical Systems, Inc.', 'Clarity Medical Systems, Inc.'
The increasing global prevalence of diabetes is a significant driver for the diabetic retinopathy market. Diabetic retinopathy is a common complication of diabetes and affects many diabetic patients. The growing diabetic population contributes to the demand for diagnostic and treatment options for diabetic retinopathy.
There is a growing recognition of the importance of early detection and intervention in diabetic retinopathy. The focus is shifting towards regular screening programs, awareness campaigns, and advanced imaging technologies for early diagnosis, enabling timely treatment and better management of the condition.
North America dominated the market, accounting for 37.8% of total revenue in 2023. Some of the market's drivers include the presence of modern healthcare infrastructure, favorable government activities pertaining to medication research, and the presence of substantial patient & practitioner awareness levels. One of the primary factors contributing to this region's huge share is the high market penetration of new goods such as anti-VEGF medications such as Lucentis, Avastin, and Eylea. High healthcare expenditure, increased patient knowledge of diabetes, the availability of well-established medical facilities, and a favorable reimbursement environment are some of the primary causes.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35A2516
[email protected]
USA +1 351-333-4748